Prostaglandin E 2 (PGE 2 ), is a major prostanoid produced by the activity of cyclooxygenases (COX) in response to various physiological and pathological stimuli. PGE 2 exerts its effects by activating four specific E-type prostanoid receptors (EP1, EP2, EP3, and EP4). In the present study, we analyzed the expression of the PGE 2 receptor EP1 (mRNA and protein) in different regions of the adult rat brain (hippocampus, hypothalamus, striatum, prefrontal cerebral cortex, parietal cortex, brain stem, and cerebellum) using reverse transcriptionpolymerase chain reaction, Western blotting, and immunohistochemical methods. On a regional basis, levels of EP1 mRNA were the highest in parietal cortex and cerebellum. At the protein level, we found very strong expression of EP1 in cerebellum, as revealed by Western blotting experiments. Furthermore, the present study provides for the first time evidence that the EP1 receptor is highly expressed in the cerebellum, where the Purkinje cells displayed very high immunolabeling of their perikaryon and dendrites, as observed in the immunohistochemical analysis. Results from the present study indicate that the EP1 prostanoid receptor is expressed in specific neuronal populations, which possibly determine the region-specific response to PGE 2 .
Introduction
Prostaglandin endoperoxide H synthases, most commonly known as cyclooxygenases (COX), catalyze the committed step in prostanoid synthesis (for a complete review, see Smith et al., 2000) . There are two known COX isoforms, COX-1 and COX-2, which are 90% similar in amino acid sequence and 60% homologous (Smith et al., 2000) . COX-1 is expressed constitutively in many organs and contributes to the Miettinen et al., 1997) , after seizures (Adams et al., 1996) , excitotoxicity (Adams et al., 1996; Miettinen et al., 1997; Sanz et al., 1997) , spreading depression (Miettinen et al., 1997) , and by cerebral ischemia (Collaco-Moraes et al., 1996; Nogawa et al., 1997; Candelario-Jalil et al., 2004) and can be induced rapidly in microglia and astrocyte cultures by a variety of stimuli (Yamagata et al., 1993; Fiebich et al., 1996; Minghetti et al., 1996; Bauer et al., 1997; O'Banion, 1999; Akundi et al., 2005) . Despite the intensive research in this area, the physiological and pathological functions of COX isoforms in the brain are not completely understood, mainly because of the complexity of the system, involving multiple pathways that produce several prostanoids from diverse cell types. In addition, the existence of different prostanoid receptors coupled to different signal transduction pathways adds to the complexity of the role of COX in physiology and/or pathophysiology.
A major product of COX activity is prostaglandin E 2 (PGE 2 ), a prostanoid that exerts its effects by activating E-type prostanoid receptors, which have been classified into four subtypes (EP1-EP4). PGE 2 receptors differ in ligand-binding specificity, tissue distribution, and coupling to intracellular signal transduction pathways Sugimoto et al., 2000) .
All EP receptors are heterotrimeric, GTP-binding protein (G protein)-coupled, rhodopsin-type receptors (Watabe et al., 1993; Sugimoto et al., 2000) . The primary signaling pathways of the four EP receptors are as follows: EP1 couples to elevation of intracellular calcium levels [Ca 2+ ] i (Funk et al., 1993) ; EP2 and EP4 couple to an increase in intracellular cAMP accumulation (Bastien et al., 1994; Regan et al., 1994) ; and EP3 couples to a decrease in intracellular cAMP concentrations (Boie et al., 1997) .
Up to now, EP receptors have been found on a cellular level only in neurons throughout the unlesioned rodent central nervous system (CNS). In contrast to EP2 and EP4 receptors, which have been found only in restricted neuronal cell groups (Zhang and Rivest, 1999) , EP3 receptors show a widespread constitutive expression in neurons throughout the brain (Ek et al., 2000; Nakamura et al., 2000) .
Unlike the other EP receptors, there is very little, if any, existing documentation on the regional distribution of EP1 in the rat brain. The purpose of the present study was therefore to identify the rat brain areas that express EP1 under basal conditions and to compare the expression levels of this prostanoid receptor (EP1 mRNA and protein) in seven discrete areas of the adult rat brain, using reverse transcription-polymerase chain reaction (RT-PCR), Western blotting, and immunohistochemistry. An analysis of the distribution of EP1 receptor in the brain is essential to assess its functional role in physiological and pathophysiological conditions.
Materials and Methods

Dissection of Rat Brain Regions
Sprague-Dawley rats of either sex were sacrificed by cervical dislocation, and seven different brain regions (hippocampus, hypothalamus, striatum, prefrontal cortex, parietal cortex, brain stem, and cerebellum) were dissected out according to the dissection method of Glowinski and Iversen (1966) , as reported in our previous studies (Candelario-Jalil et al., 2001a , 2001b . Tissue samples were placed immediately in liquid N 2 and later kept at -80°C until further analysis.
RNA Extraction and RT-PCR Analysis
Total RNA from brain regions was extracted using the guanidine isothiocyanate method according to Chomczynski and Sacchi (1987) . For RT-PCR, 2 µg of total RNA was reverse transcribed using Moloney murine leukemia virus reverse transcriptase (Promega, Mannheim, Germany) and random hexamers (Promega). PCR was carried out using Taq polymerase (Promega) and dNTP master mix (Invitek, Berlin, Germany). Primers were designed using PrimerSelect Software from DNA Star (Madison, WI). The following specific primers for rat EP1 receptor were used: forward, 5'-CTGGGCGGCTGCATGGTCTTCTTT-3'; reverse, 5'-GCGGAGGGCAGCTGTGGTTGA-3' (65°C, 40 cycles, product length: 497 bp). Equal equilibration was determined using rat β-actin primers (forward, 5'-ATGGATGACGATATCGCT-3'; reverse, 5'-ATGAGGTAGTCTGTCAGGT-3' [48°C, 30 cycles, amplicon size 569 bp]). PCR products were separated electrophoretically on a 2% agarose gel. Potential contamination by genomic DNA was controlled by omitting RT and using βactin primers in the subsequent PCR amplification. Only RNA samples showing no bands after this procedure were used for further investigation.
Western Blot analysis
Brain regions were dissected out as described above, diluted 1:10 (w/v) with SDS-sample buffer (42 mM Tris-HCl at pH 6.8, 1.3% SDS buffer, 100 µM orthovanadate, 6.5% glycerine [Laemmli, 1970] ), and homogenized with a sonicator (Branson Sonifier 250 at the 50% pulse mode with a microtip [Branson, Danbury, CT]). Tissue homogenates were centrifuged at 14,000 rpm at 4°C for 10 min, and supernatants were taken for analysis. Protein content was determined using the bicinchoninic acid method (BCA Protein Assay Kit [Pierce, distributed by KFC Chemikalien, Munich, Germany]). Before loading, samples were incubated at 95°C for 5 min. Sixty micrograms of protein was subjected to SDS-PAGE on a 10% gel under reducing conditions. Proteins were transferred onto a polyvinylidene fluoride membrane (Millipore, Bedford, MA) by semidry blotting. The membrane was blocked overnight at 4°C using Rotiblock (Roth, Karlsruhe, Germany). Rabbit anti-EP1 receptor polyclonal antibody (Cayman, Ann Arbor, MI) was diluted (1:500) in TBS/Tween-20 containing 1% BSA. Membranes were incubated for 2 h at room temperature with the primary antibody, washed three times in TBS/Tween-20, and incubated for 1 h with the secondary antibody, horseradish peroxidase (HRP)-linked anti-rabbit IgG (Amersham Biosciences, Freiburg, Germany). Subsequent detection was performed using the ECL Western blotting system (Amersham Biosciences), according to the manufacturer's instructions. Specificity of the antibody was assessed by omitting the first antibody in Western blotting experiments. All Western blot experiments were carried out in brain areas from three different rats. Quantification of the Western blots was performed using ScanPack 3.0 software (Biometra, Göttingen, Germany), and for descriptive purposes means and standard deviations were calculated.
EP1 Immunohistochemical Analysis
Animals were deeply anesthetized with chloral hydrate (300 mg/kg; i.p.) and were intracardially perfused with cold PBS, followed by 4% (w/v) paraformaldehyde (PFA) in PBS. Brains were removed and immersed in 4% PFA/PBS for another 2 d at 4°C. After cryoprotection in 20% sucrose for at least 2 d, the brains were frozen rapidly in isopentane and stored at -80°C. Sagittal cryostat sections (10 µm) were cut, mounted on Superfrost sections, and processed for immunohistochemistry with the avidin/biotin/HRP method according to the manufacturer 's instructions as described previously (Slawik et al., 2004) . First, sections were reacted in 1% H 2 O 2 to quench endogenous peroxidase activity for 20 min. After washing, nonspecific binding sites were blocked by incubation with 4% respective normal serum in PBS for 30 min. Sections were incubated overnight at 4°C with the primary antibody (rabbit polyclonal antibody against EP1 [Cayman Chemical], diluted 1:300) in 1% bovine serum albumin (BSA) in PBS. After incubation with the primary antibody, sections were washed three times and incubated with the secondary antibody (goat anti-rabbit [Santa Cruz Biotechnology], diluted 1:200) for 1 h. After three washes, sections were incubated for 30 min with the avidin-biotinylated HRP complex (ABC-Elite kit, Vector Laboratories, Burlingame, CA). All washes between antibody incubations were made in PBS. For visualization of peroxidase, all sections were incubated with 0.05% diaminobenzidine and 0.02% H 2 O 2 . Counterstaining was performed with Mayer 's hematoxylin. After dehydration, sections were coverslipped with Vitro-Clud ® mounting media (Emmendingen, Germany). Negative controls, consisting of sections incubated in the absence of primary antibodies, gave no signal and thus confirmed the specificity of the antigenantibody-binding signal shown here (Fig. 3 ).
Results and Discussion
Using semiquantitative RT-PCR, we observed the presence of single transcripts for EP1 (497 bp) and βactin (569 bp) migrating at the predicted position ( Fig.  1 ). EP1 mRNAwas detected in all brain samples examined, although there were marked differences in the level of expression of this prostanoid receptor among the cerebral regions studied. On a regional basis, the strongest levels of EP1 mRNA were found in parietal cortex and cerebellum, followed in descending order by frontal cortex and striatum (Fig. 1) . The hypothalamus, hippocampus, and brain stem displayed a low-level EP1 mRNA signal, as depicted in Fig. 1 .
To confirm that the pattern of EP1 mRNA expression is also observed at the protein level, we performed Western blotting of lysates prepared from different brain areas. The result of a representative Western blotting experiment is shown in Fig. 2 . In line with the data observed at the mRNA level, we found pronounced cerebellar levels of the EP1 protein, which was consistent in all animals studied. Although EP1 protein was also observed in parietal cortex, it did not correspond to the strong mRNA signal in this area (Fig. 2) , which was comparable to cerebellum (Fig. 1) . On the other hand, our results showed very weak EP1 protein expression in the 306 Candelario-Jalil et al.
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Volume 27, 2005 other brain regions under study (Fig. 2) , which fit with the mRNA findings (Fig. 1) . In addition, we performed an immunohistochemical analysis to further confirm the results of the Western blotting on a cellular level. Few EP1-positive cells were observed in parietal cortex, and very few immunopositive cells were found in the other regions studied (data not shown). In contrast, and in line with our results from mRNA and Western blot studies, EP1 receptor immunoreactivity was found markedly in the cerebellum, where the Purkinje cells displayed very high immunolabeling of their perikaryon and dendrites, as observed in Fig. 3 . No other cell types in the cerebellum showed immunostaining for EP1.
To the best of our knowledge, this is the first study to consistently characterize the expression of the EP1 receptor in different areas of the rat brain. It is important to mention that compared with all of the other brain regions examined, levels of EP1 protein were the highest in the cerebellum. The physiological function of the increased EP1 levels in cerebellum is not clear at this time. One of the hallmarks of cerebellar Purkinje cells is their ability to express a characteristic form of activity-dependent synaptic plasticity, termed longterm depression (LTD), which is essential for motor learning. The cerebellum is the brain region in which learned movements are stored, and LTD is a key mechanism involved in this function (Saab and Willis, 2003) . Synaptically induced dendritic Ca 2+ signaling has been known for a long time to be a critical step in LTD induction (Sakurai, 1990; Konnerth et al., 1992) . Experimental evidence indicates that not merely the lack of synaptically mediated Ca 2+ signaling in Purkinje cells, but also a change in the temporal dynamics of postsynaptic Ca 2+ transients after genetic deletion of the calcium-binding protein calbindin D-28k (calbindin), might cause impairment of motor coordination (Airaksinen et al., 1997; Barski et al., 2003) . PGE 2 stimulates Ca 2+ mobilization via EP1 receptor (Watabe et al., 1993; Katoh et al., 1995) , but the mechanism of the increase in intracellular Ca 2+ and the identification of a G protein that interacts with the EP1 receptor remains to be elucidated. EP1induced Ca 2+ influx correlates with only a small increase in inositol-1,4,5-trisphos-phate generation and is dependent on the presence of extracellular Ca 2+ . It is thus believed that the EP1 receptor couples to Ca 2+ through a mechanism independent of G q protein (Narumiya et al., 1999) .
Because EP1 activation is linked to an increase in intracellular Ca 2+ levels, we speculate that PGE 2 might be involved in the modulation of neuronal plasticity of Purkinje cells through activation of EP1 receptors. The EP1 receptor appears to be the most likely candidate because of its high expression in these cells, as shown here (Fig. 3) and because of the very low or null expression of the other EP receptors (EP2-EP4) in cerebellum (Zhang and Rivest, 1999; Ek et al., 2000) .
The notion that PGE 2 could modulate synaptic plasticity in cerebellum is based on previous studies on the role of this prostanoid in long-term potentiation (LTP) in hippocampus (another example of synaptic plasticity and of the putative biological processes underlying memory). It has been shown previously that COX-2, but not COX-1, mediates PGE 2 signaling in hippocampal long-term synaptic plasticity (Chen et al., 2002) . Selective inhibitors of COX-2 reduced membrane excitability significantly, backpropagating dendritic action potential-associated Ca 2+ influx and LTP induction in hippocampus, whereas a COX-1 inhibitor was ineffective. All of these effects were effectively reversed by exogenous application of PGE 2 but not by other prostaglandins (Chen et al., 2002) . Similar results were found by Shaw et al. (2003) , suggesting that PGE 2 plays an important regulatory role in synaptic plasticity.
Because PGE 2 is not stored or secreted from synaptic vesicles like the classic neurotransmitters, and rapidly diffuses and activates EP receptors, some investigators have suggested that PGE 2 signaling must depend on basal COX-2 expression. Interestingly, COX-2 mRNA and protein are normally expressed in relatively high levels in several neuronal populations throughout the CNS (Yamagata et al., 1993; Breder et al., 1995) , and COX-2 is consistently localized in dendritic spines of neurons that receive synaptic input, including Purkinje cells (Kaufmann et al., 1996; Pardue et al., 2003) . PGE 2 is also involved in the regulation of membrane excitability in sensory neurons (Gold et al., 1998; Nicol et al., 1997) . Furthermore, through its action on EP1 receptors, PGE 2 induces Ca 2+ release from intracellular ryanodine/caffeine-sensitive stores and stimulates catecholamine release in adrenal medullary cells (Negishi et al., 1990; Shibuya et al., 1999) .
Some of the detrimental effects of PGE 2 have been associated with its ability to bind predominantly to EP1 receptors. These effects include PGE 2 -mediated fever (Oka and Hori, 1994; Batshake et al., 1995) , allodynia (Minami et al., 2001) , and acute inflammatory pain (Stock et al., 2001) . Results from very recent studies indicate that activation of EP1 receptors contributes to COX-2-dependent neurotoxicity following excitotoxic neuronal injury in vitro (Carlson, 2003; Zhou et al., 2004) and in vivo (Kawano et al., 2004) . The mechanisms by which EP1 receptors promote neuronal injury are likely to include amplification of the intracellular Ca 2+ levels induced by excitotoxicity (Kawano et al., 2004) .
The present study provides evidence that the EP1 receptor is highly expressed in Purkinje cells of the rat cerebellum, which could inspire new investigations to elucidate the specific role of PGE 2 /EP1 signaling in these cells. A deeper understanding of Purkinje cell physiology, including a delineation of the whole spectrum of signal transduction pathways, is essential in understanding the organization of cerebellar circuits.
As demonstrated here, the other rat brain areas examined showed only low EP1 expression under normal conditions (Figs. 1 and 2) . Only the parietal cortex displayed a very strong mRNA signal (compared with the signal observed in cerebellum), but results from the Western blotting and immunohistochemical analyses showed that EP1 protein expression is relatively low compared with cerebellum. This suggests that expression of the EP1 receptor might not be regulated only at the transcriptional level. Some factors such as region-specific changes in mRNA translation, posttranslational modification, and/or processing of the EP1 protein into functional membrane receptors might also be involved and could explain this observation.
In summary, results from the present study indicate that the EP1 prostanoid receptor is expressed in specific neuronal populations, which possibly determine the region-specific response to PGE 2 . The present findings lay the foundation for future studies aimed at explaining the cellular and molecular mechanisms by which PGE 2 , through its interaction with EP1 receptors, could modulate neuronal function.
